The Chemours Company cash flow to debt ratio of 5.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

The Chemours Company's free cash flow has increased -105.14% from $-993.00M last year to $51.00M, signaling increasing performance

The Chemours Company's debt to equity ratio is -82.92, signaling that the company spent its equity and risk bankruptcy.

The Chemours Company's debt to equity ratio is -82.92, signaling that the company spent its equity and risk bankruptcy.

The Chemours Company has a net debt to EBITDA ratio of 11.79x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

The Chemours Company's interest coverage ratio is -1.11, which means that the company struggles to meet interest obligations, signaling financial risk.

The Chemours Company's profit margin has decreased (452.57%) in the last year from 1.49% to -5.24%, signaling decreasing performance

The Chemours Company's short-term assets of $3.00B exceed its short-term liabilities of $1.69B

The Chemours Company's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

The Chemours Company's return on equity of -170.31%, is lower than 15.00%, indicating bad performance

The Chemours Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

The Chemours Company had positive net income in 3 out of 5 years, indicating stable and consistent earnings

The Chemours Company has positive free cash flow, indicating the company generates cash after capital expenditures

The Chemours Company has a free cash flow yield of 2.32%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

The Chemours Company's yearly earnings has decreased 548.84% since last year from $86.00M to $-386.00M, signaling decreasing performance

The Chemours Company's yearly revenue has increased 0.45% since last year from $5.78B to $5.81B, signaling increasing performance

ROIC -5.71% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

The Chemours Company's 3-year revenue CAGR of -5.26% is negative, indicating declining revenue over the past 3 years

The Chemours Company had revenue growth in 3 out of 5 years, indicating consistent revenue performance

The Chemours Company had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

The Chemours Company has insufficient data to evaluate this check.

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

The Chemours Company has an EV/EBITDA ratio of 18.39x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

The Chemours Company is undervalued relative to its fair value price of 39.44 based on Earnings Fair Value model

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company has negative shareholder equity; price-to-book is not meaningful and the check fails

The Chemours Company has a price-to-sales ratio of 0.38x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue